immuron limited, page-5

100% agree with all of the above.

The market can have a very long memory, and PXS was > $1 once upon a time. The trouble is that it ended up disappointing a lot of people. Whilst PXS is a turnaround story in the making, turnaround stories can take many years to get back to where they were before. Just ask anyone that held onto ELD for the last 10 years or so.

Once PXS earns a couple of more milestone payments from Boehringer Ingleheim, or does a similar deal with another Big Pharma in relation to one of its other products currently under development, then - and only then - will see a sustainable push towards $1 IMHO.

GLTAH.